Systemic anti-cancer therapy: management options for people with non-squamous (adenocarcinoma, large cell undifferentiated) carcinoma and non-small-cell carcinoma (non-otherwise specified) – November 2021 update

**EGFR-TK positive**
- Atezolizumab (no PD-L1 expression needed) (TA520) or Nivolumab (if PD-L1 >1%) (TA713) or Pembrolizumab (if PD-L1 >1%) (TA428)

**ALK positive**
- Atezolizumab (no PD-L1 expression needed) (TA520) or Nivolumab (if PD-L1 >1%) (TA713) or Pembrolizumab (if PD-L1 >1%) (TA428)

**ROS-1 positive**
- Crizotinib (TA529) or Entrectinib (TA643)

**T790M positive?**
- **Y**
  - Osimertinib (TA653)

**Disease progression**
- Platinum doublet chemotherapy* (when using Pemetrexed+Cisplatin as first-line treatment see TA181)
- Pemetrexed+ Carboplatin*
- Atezolizumab + bevacizumab, carboplatin and paclitaxel* (TA584)

**Cancer Drugs Fund**
- This combination/some of these combinations of drugs do not have a UK marketing authorisation for 1 or more indications

**New addition**
- Alectinib (TA536) or Brigatinib (TA670) or Ceritinib (TA500)
- Crizotinib (TA406)
- Brigatinib (TA571) or Ceritinib (TA395)
- Lorlatinib* (TA628)
- Docetaxel +/- Nintedanib (TA347)
- Nintedanib (TA347)


NICE National Institute for Health and Care Excellence

This is page 1 of a 2-page summary of the drug treatment options for people with non-squamous and non-small-cell carcinoma in line with the NICE guideline on lung cancer. It also covers recommendations from technology appraisals published since 2009. Please refer to NICE technology appraisals and the NHS England website for information on eligibility, patient access schemes and more. See the NICE Pathway on lung cancer for an integrated view of all NICE recommendations on lung cancer. © NICE 2021. All rights reserved. Subject to Notice of rights.